baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Heidelberg Pharma AG/ DE000A11QVV0 /

6/6/2024 5:28:59 PM	Chg. 0.0000	Volume	Bid9:38:49 PM	Ask9:38:49 PM	Market Capitalization	Dividend Y.	P/E Ratio
2.9000EUR	0.00%	2,500 Turnover: 7,255	2.8500Bid Size: 1,100	3.0400Ask Size: 1,100	100.82 mill.EUR	0.00%	-

GlobeNewswire 5/26/2021 Immatics Announces Changes to its Board of Directors

GlobeNewswire 3/11/2020 RedHill Biopharma Provides Update on Opaganib (Yeliva®)

GlobeNewswire 10/19/2018 ADC Contract Manufacturing Market, 2030

GlobeNewswire 7/17/2018 APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

GlobeNewswire 11/16/2017 Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%

GlobeNewswire 8/24/2017 Global Cell Line Development Services Market, 2027

GlobeNewswire 7/6/2017 Biopharmaceutical Contract Manufacturing Market, 2027

GlobeNewswire 11/12/2007 HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE

GlobeNewswire 5/21/2007 Clinical effectiveness and tolerability of Fosalvudine (HIV) confirmed

GlobeNewswire 5/17/2007 Fosfluridine Tidoxil shows effectiveness in Actinic Keratosis

GlobeNewswire 2/5/2007 Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis

GlobeNewswire 1/10/2007 Heidelberg Pharma becomes a Corporation

GlobeNewswire 10/9/2006 Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients

GlobeNewswire 10/2/2006 Heidelberg Pharma raises 16 million EUR (20 million USD) in series B-Round

Heidelberg Pharma AG/ DE000A11QVV0 /

If you wish to receive reply to your feedback, please provide your email address.